Susquehanna International Group’s Zevra Therapeutics ZVRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.74M | Sell |
186,582
-106,513
| -36% | -$960K | ﹤0.01% | 6504 |
|
|
2025
Q4 | $2.63M | Sell |
293,095
-912,419
| -76% | -$8.63M | ﹤0.01% | 5119 |
|
|
2025
Q3 | $11.5M | Buy |
1,205,514
+1,044,021
| +646% | +$10.5M | ﹤0.01% | 2871 |
|
|
2025
Q2 | $1.42M | Sell |
161,493
-3,922
| -2% | -$31.8K | ﹤0.01% | 6585 |
|
|
2025
Q1 | $1.24M | Buy |
165,415
+60,785
| +58% | +$483K | ﹤0.01% | 6720 |
|
|
2024
Q4 | $873K | Sell |
104,630
-110,168
| -51% | -$940K | ﹤0.01% | 7309 |
|
|
2024
Q3 | $1.49M | Buy |
214,798
+76,294
| +55% | +$518K | ﹤0.01% | 5924 |
|
|
2024
Q2 | $679K | Buy |
138,504
+49,895
| +56% | +$236K | ﹤0.01% | 7505 |
|
|
2024
Q1 | $514K | Sell |
88,609
-26,253
| -23% | -$161K | ﹤0.01% | 8445 |
|
|
2023
Q4 | $752K | Buy |
114,862
+70,457
| +159% | +$330K | ﹤0.01% | 7686 |
|
|
2023
Q3 | $214K | Buy |
44,405
+2,619
| +6% | +$13.1K | ﹤0.01% | 10087 |
|
|
2023
Q2 | $213K | Sell |
41,786
-159,386
| -79% | -$859K | ﹤0.01% | 10153 |
|
|
2023
Q1 | $1.11M | Buy |
201,172
+31,158
| +18% | +$165K | ﹤0.01% | 6541 |
|
|
2022
Q4 | $780K | Buy |
170,014
+25,269
| +17% | +$128K | ﹤0.01% | 6724 |
|
|
2022
Q3 | $903K | Sell |
144,745
-19,156
| -12% | -$108K | ﹤0.01% | 6905 |
|
|
2022
Q2 | $731K | Sell |
163,901
-25,061
| -13% | -$114K | ﹤0.01% | 7301 |
|
|
2022
Q1 | $950K | Buy |
188,962
+114,913
| +155% | +$731K | ﹤0.01% | 7265 |
|
|
2021
Q4 | $645K | Sell |
74,049
-427,882
| -85% | -$3.82M | ﹤0.01% | 8474 |
|
|
2021
Q3 | $4.68M | Buy |
501,931
+142,870
| +40% | +$1.44M | ﹤0.01% | 4069 |
|
|
2021
Q2 | $4.6M | Buy |
359,061
+162,002
| +82% | +$1.74M | ﹤0.01% | 4177 |
|
|
2021
Q1 | $1.81M | Buy |
+197,059
| New | +$1.72M | ﹤0.01% | 6157 |
|
|
2020
Q2 | – | Sell |
-3,608
| Closed | -$13K | – | 11070 |
|
|
2020
Q1 | $13K | Sell |
3,608
-423
| -10% | -$2.34K | ﹤0.01% | 10010 |
|
|
2019
Q4 | $24K | Sell |
4,031
-2,510
| -38% | -$19.9K | ﹤0.01% | 9471 |
|
|
2019
Q3 | $72K | Buy |
6,541
+4,148
| +173% | +$75K | ﹤0.01% | 9684 |
|
|
2019
Q2 | $67K | Sell |
2,393
-5,715
| -70% | -$144K | ﹤0.01% | 9767 |
|
|
2019
Q1 | $217K | Buy |
8,108
+4,783
| +144% | +$176K | ﹤0.01% | 7765 |
|
|
2018
Q4 | $95K | Buy |
3,325
+616
| +23% | +$24.9K | ﹤0.01% | 8247 |
|
|
2018
Q3 | $208K | Buy |
2,709
+1,875
| +225% | +$146K | ﹤0.01% | 8150 |
|
|
2018
Q2 | $87K | Buy |
+834
| New | +$81.4K | ﹤0.01% | 9096 |
|
|
2018
Q1 | – | Sell |
-1,068
| Closed | -$69K | – | 10316 |
|
|
2017
Q4 | $69K | Buy |
+1,068
| New | +$64.4K | ﹤0.01% | 8827 |
|
|
2016
Q2 | – | Sell |
-3,082
| Closed | -$715K | – | 9460 |
|
|
2016
Q1 | $715K | Buy |
3,082
+1,500
| +95% | +$363K | ﹤0.01% | 5754 |
|
|
2015
Q4 | $503K | Buy |
+1,582
| New | +$429K | ﹤0.01% | 6759 |
|
Other funds holding ZVRA
WP
NCM
VCM
ACM
Susquehanna International Group's ZVRA Position: Q1 2026 in Review
Susquehanna International Group reduced its Zevra Therapeutics (ZVRA) stake by 36% in Q1 2026, selling an estimated $960K and leaving 186,582 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #6504.
Susquehanna International Group first reported a position in ZVRA in Q4 2015 and has held it in 32 quarters since. The position peaked at $11.5M in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.
- Susquehanna International Group held 186,582 shares of Zevra Therapeutics worth $1.74M as of Q1 2026.
- Susquehanna International Group sold 106,513 Zevra Therapeutics shares in Q1 2026, an estimated $960K.
- Zevra Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6504 holding.
- Susquehanna International Group first reported a position in Zevra Therapeutics in Q4 2015 and has held it in 32 quarters since.
- Susquehanna International Group's Zevra Therapeutics position peaked at $11.5M in Q3 2025.
- 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.